NCT00180232撤回不适用
An Open Clinical Trial to Assess the Influence of Newly Prescribed Aminobiphosphonates on Arterial Stiffness (Changes of the Aortal Elasticity Due to a Newly Established Aminobiphosphinate Therapy for the Treatment of Osteoporosis)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
研究概览
简要总结
The study tries to reveal if aminobisphosphonates influence aside the bone density also the vascular status in the typical elderly patient population
详细描述
The subjects - starting bisphosphonate treatment due to medical reasons - will be additionally investigated as outpatients (arterial stiffness, applanation tonometry), for each subject 3 individual dates with a duration of approx. 30 min each are scheduled, prior to therapy with bisphosphonate, after 3 and 6 month of treatment
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
排除标准
- •patients with major cardiovascular disease patients participating in another clinical trial 1month prior to inclusion in this study patients unable or unwilling to give informed consent
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for JapaneseOsteoporosisNCT02166437Tomidahama Hospital500
招募中
3 期
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric SurgeryBone LossNCT04922333Wake Forest University Health Sciences200
已完成
不适用
Efficacy and Safety on the Use of Bisphosphonates in PaediatricsBone FragileBisphosphonate-Associated OsteonecrosisChildrenAdverse EventsNCT04012320Centre Hospitalier Universitaire de Nīmes99
已完成
4 期
Bisphosphonate Therapy for Osteogenesis ImperfectaPaget Disease of BoneOsteoporosisOsteogenesis ImperfectaNCT00159419Indiana University School of Medicine18
已完成
2 期
Bisphosphonate Treatment of Osteogenesis ImperfectaOsteogenesis ImperfectaNCT00063479Novartis Pharmaceuticals158